Search company, investor...

Predict your next investment

Corporation
hbl.co.il

Investments

15

Portfolio Exits

2

Partners & Customers

2

About Hadasit Bio Holdings

Hadasit Bio-Holdings Ltd. was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for much of Israel's hospital-based translational research.

Headquarters Location

Jerusaelm Bio-Park, 5th Floor Hadassah Ein-Kerem Campus

91120,

Israel

Want to inform investors similar to Hadasit Bio Holdings about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Hadasit Bio Holdings News

Techtalk with Tamar Raz about technology transfer in Israel

Aug 3, 2022

03 August 2022 “Israel is a very, very entrepreneurial country. Many people are inventors, many people are not afraid to start new things. And people are not afraid to fail. We think that learning from your failure is very, very important.” - Tamar Raz, CEO at Hadasit Medical Research Services & Development You can also listen to this podcast episode on Apple  and Google . SUBSCRIBE in order not to miss any new one: This episode of Techtalk features Tamar Raz, CEO at Hadasit Medical Research Services & Development, the technology transfer company of Hadassah University Hospitals in Jerusalem, and a Technology Transfer Expert with nearly 20 years of experience leading business transactions and management in the biotech and life sciences sector. Tamar is also the Director of KAHR-medical Ltd. and she serves as the chairperson of Hadasit Bio Holdings, a public holding company allowing public participation in the promising field of biotechnology. This conversation covers Tamar’s point of view about the technology transfer in Israel and her remarkable experience as an expert and entrepreneur who brings medical innovations from the laboratory to the market. Tamar starts with an historical overview of the technology transfer sector in Israel and continues by giving us precious insights about the technology transfer infrastructure, steps, phases and key departments. We discuss not only the basics of technology transfer, but also more advanced industry activities like the incubation or acceleration programmes, that can not exist without the infrastructure described before. IBM Alpha Zone - the first accelerator that IBM built in the world, located in Israel - is a great example. Moreover, Tamar shares lessons about how a technology transfer center like Hadasit can become financially sustainable and the importance of a flexible business model that means long-term investment and short-term activities that bring revenues. “We worked in Hadassah, in the last 4 or 5 years, to enlarge the innovation ecosystem of Hadassah. So, we want to bring companies to work with us not only based on our IP, but also based on their IP, on their ideas. Because we believe that connecting the physicians and professors of Hadasa to the industry and to the start-up companies, we create a cycle of innovation at Hadassah that will bring us more work and will bring us more revenues. But also we create better inventors that will think about the new ideas all the time”, Tamar explains. Tune in to find Tamar’s favorite Hadasit success story and:  Historic overview of how Israel became such a great example of technology transfer (04:30) How the technology transfer infrastructure was built (10:30) The universities input in creating technology transfer departments (18:30) The first steps that Romania, or other countries with an undeveloped technology transfer sector, should take (26:00) Key departments for successful technology transfer (35:30) The differentiators of an incubation or acceleration programmes (39:00) Why Digital Health? (41:00) What makes a technology transfer center like Hadasit financially sustainable? (45:00) Tamar’s favorite Hadasit success story (48:30) The economic impact of the technology transfer in Israel (57:30)

Hadasit Bio Holdings Investments

15 Investments

Hadasit Bio Holdings has made 15 investments. Their latest investment was in KAHR as part of their Series D on June 6, 2021.

CBI Logo

Hadasit Bio Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/16/2021

Series D

KAHR

$46.5M

No

15

2/25/2020

Series C

KAHR

$18M

No

4

9/19/2017

Series B

Enlivex Therapeutics

$10M

No

3

9/10/2013

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

1/22/2013

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2021

2/25/2020

9/19/2017

9/10/2013

1/22/2013

Round

Series D

Series C

Series B

Series A - III

Convertible Note

Company

KAHR

KAHR

Enlivex Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$46.5M

$18M

$10M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

4

3

10

10

Hadasit Bio Holdings Portfolio Exits

2 Portfolio Exits

Hadasit Bio Holdings has 2 portfolio exits. Their latest portfolio exit was Enlivex Therapeutics on March 26, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/26/2019

Reverse Merger

$99M

7

11/11/2012

Corporate Majority - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/26/2019

11/11/2012

Exit

Reverse Merger

Corporate Majority - II

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

7

10

Hadasit Bio Holdings Acquisitions

1 Acquisition

Hadasit Bio Holdings acquired 1 company. Their latest acquisition was Cell Cure Neurosciences on October 10, 2010.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/10/2010

$99M

Corporate Majority

Date

10/10/2010

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Corporate Majority

Sources

Hadasit Bio Holdings Partners & Customers

2 Partners and customers

Hadasit Bio Holdings has 2 strategic partners and customers. Hadasit Bio Holdings recently partnered with Cell Cure Neurosciences, and Teva Pharmaceuticals on October 10, 2010.

Date

Type

Business Partner

Country

News Snippet

Sources

10/10/2010

Licensor, and Licensee

Israel

1

7/30/2007

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

10/10/2010

7/30/2007

Type

Licensor, and Licensee

Partner

Business Partner

Country

Israel

United Kingdom

News Snippet

Subscribe to see more

Subscribe to see more

Sources

1

10

Hadasit Bio Holdings Team

3 Team Members

Hadasit Bio Holdings has 3 team members, including current Chief Financial Officer, Yoram Azulai.

Name

Work History

Title

Status

Yoram Azulai

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Yoram Azulai

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.